↓ Skip to main content

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

Overview of attention for article published in Journal of Translational Medicine, October 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
3 X users
patent
2 patents

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
91 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Published in
Journal of Translational Medicine, October 2014
DOI 10.1186/s12967-014-0277-z
Pubmed ID
Authors

Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, Carlo Bifulco, Alistair Cochran, Claus Garbe, Alexander M Eggermont, Mark Faries, Soldano Ferrone, Jeffrey E Gershenwald, Thomas F Gajewski, Ruth Halaban, F Stephen Hodi, Richard Kefford, John M Kirkwood, James Larkin, Sancy Leachman, Michele Maio, Richard Marais, Giuseppe Masucci, Ignacio Melero, Giuseppe Palmieri, Igor Puzanov, Antoni Ribas, Yvonne Saenger, Bastian Schilling, Barbara Seliger, David Stroncek, Ryan Sullivan, Alessandro Testori, Ena Wang, Gennaro Ciliberto, Nicola Mozzillo, Francesco M Marincola, Magdalena Thurin

Abstract

The fourth ¿Melanoma Bridge Meeting¿ took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers.Until recently systemic therapy for metastatic melanoma patients was ineffective, but recent research in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, such as mitogen-activated protein kinase (MAPK) pathway inhibitors, like BRAF and MEK inhibitors, as well as other signaling pathways inhibitors, are being tested in metastatic melanoma either as monotherapy or in combination, and have yielded promising results.Improved survival rates have also been observed with immune therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demonstrate clinical benefit in melanoma as well.This meeting¿s specific focus was on advances in targeted therapy and immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, prognosis and prediction of treatment response was an integral part of the meeting. Significant consideration was given to issues surrounding the development of novel therapeutic targets as further study of patterns of resistance to both immunologic and targeted drugs are paramount to future drug development to guide existing and future therapies. The overall emphasis on biomarkers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy in melanoma.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 1 1%
United States 1 1%
Unknown 89 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 16%
Student > Ph. D. Student 14 15%
Student > Bachelor 14 15%
Student > Master 10 11%
Student > Doctoral Student 9 10%
Other 15 16%
Unknown 14 15%
Readers by discipline Count As %
Medicine and Dentistry 26 29%
Biochemistry, Genetics and Molecular Biology 15 16%
Agricultural and Biological Sciences 11 12%
Immunology and Microbiology 9 10%
Computer Science 3 3%
Other 11 12%
Unknown 16 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2021.
All research outputs
#4,285,424
of 23,577,654 outputs
Outputs from Journal of Translational Medicine
#705
of 4,185 outputs
Outputs of similar age
#48,316
of 262,102 outputs
Outputs of similar age from Journal of Translational Medicine
#17
of 93 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,185 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,102 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.